Oppenheimer Reiterates Outperform Rating, $98 PT for Humana

In a quarterly update published earlier today, Oppenheimer & Co, Inc. reiterated its Outperform rating and $98.00 price target for Humana, Inc. HUM. Oppenheimer said in its update “Operationally, Humana is in a strong position due to a solid core Medicare Advantage business and its other diversified business lines. Furthermore, we believe the company is positioned to benefit from several organic growth initiatives, as well as lead an industry consolidation over the coming years. We like Humana operationally and feel it will continue to be a leading consolidator among MA plans and other types of facilities.” Humana, Inc. closed on Friday at $87.82.